Suven Life Sciences Ltd. — Investor Relations & Filings
Suven Life Sciences Ltd. focuses on the discovery and development of novel therapeutic agents for Central Nervous System (CNS) disorders. The company specializes in New Chemical Entity (NCE) research, targeting unmet medical needs in conditions such as Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s disease, and depression. Its clinical pipeline includes lead candidates like Masupirdine (SUVN-502) for cognitive impairment and Samelisant (SUVN-G3031) for narcolepsy. Suven utilizes an integrated drug discovery platform and maintains a significant global intellectual property portfolio. The organization provides drug discovery and development support services, leveraging expertise in medicinal chemistry and pharmacology to advance internal programs and collaborative research initiatives.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Copy of Newspaper Publication | 2026-04-23 | English | |
| Price movement | 2026-04-08 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | |
| Trading Window | 2026-03-27 | English | |
| Outcome of Board Meeting | 2026-03-06 | English | |
| Allotment of Securities | 2026-03-06 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42171737 | Copy of Newspaper Publication | 2026-04-23 | English | ||
| 42187106 | Price movement | 2026-04-08 | English | ||
| 42208254 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | ||
| 42223422 | Trading Window | 2026-03-27 | English | ||
| 42197228 | Outcome of Board Meeting | 2026-03-06 | English | ||
| 42197303 | Allotment of Securities | 2026-03-06 | English | ||
| 42168398 | Copy of Newspaper Publication | 2026-02-19 | English | ||
| 42295958 | Price movement | 2026-02-06 | English | ||
| 42221508 | Monitoring Agency Report | 2026-02-03 | English | ||
| 42258219 | Copy of Newspaper Publication | 2026-01-30 | English | ||
| 42179002 | Appointment | 2026-01-29 | English | ||
| 42179326 | Resignation | 2026-01-29 | English | ||
| 42179815 | Outcome of Board Meeting | 2026-01-29 | English | ||
| 42180211 | Outcome of Board Meeting | 2026-01-29 | English | ||
| 42229887 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-01-06 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AnorMED Inc.
Developed small molecule therapeutics for serious diseases,…
|
— | CA | Professional, scientific and te… |
|
ANTEOTECH LTD
Develops nanoglue technology for life sciences and lithium-…
|
ADO | AU | Professional, scientific and te… |
|
Anthem Biosciences Limited
Integrated CRAMS organization for drug discovery, developme…
|
ANTHEM | IN | Professional, scientific and te… |
|
APPLIED DNA SCIENCES INC
Develops and manufactures DNA-based technologies for geneti…
|
APDN | US | Professional, scientific and te… |
|
Aprea Therapeutics, Inc.
Clinical-stage biopharma developing cancer therapeutics via…
|
APRE | US | Professional, scientific and te… |
|
AprilBio Co.,Ltd.
Develops long-acting biologic drugs for autoimmune diseases…
|
397030 | KR | Professional, scientific and te… |
|
Aptahem AB
A clinical-stage biotech developing aptamer-based drugs for…
|
APTA | SE | Professional, scientific and te… |
|
APTAMER GROUP PLC
Develops custom affinity binders for research, diagnostics,…
|
APTA | GB | Professional, scientific and te… |
|
Aptevo Therapeutics Inc.
Clinical-stage biotech developing antibody-based immunother…
|
APVO | US | Professional, scientific and te… |
|
Aptose Biosciences Inc.
Clinical-stage company developing targeted precision medici…
|
APS | CA | Professional, scientific and te… |
Suven Life Sciences Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61491/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61491 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61491 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61491 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61491}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Suven Life Sciences Ltd. (id: 61491)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.